UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 25, 2019
Ra Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38677 | 38-3661826 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2070 Las Palmas Drive
Carlsbad, California 92011
(Address of principal executive offices, including zip code)
(760) 804-1648
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 25, 2019, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Ra Medical Systems, Inc. (the “Company”) approved the following cash bonus payments for the 2018 fiscal year to certain employees of the Company, including the Company’s named executive officers and chief financial officer. Bonus payments were based on the Committee’s evaluation of each executive’s performance and Company accomplishments during 2018, including completion of the Company’s initial public offering, with reference to the bonus targets in each executive’s employment agreement.
| Name and principal position |
2018 Bonus(1) | |||
| Dean Irwin, Chief Executive Officer |
$ | 175,200 | ||
| Jeffrey Kraws, Co-President |
$ | 114,000 | ||
| Andrew Jackson, Chief Financial Officer |
$ | 109,494 | ||
| Melissa Burstein, Executive Vice President |
$ | 77,000 | ||
| (1) | Bonuses are expected to be paid, less applicable withholdings, in the first half of March. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RA MEDICAL SYSTEMS, INC. | ||||||
| Date: January 31, 2019 |
By: | /s/ Daniel Horwood | ||||
| Daniel Horwood General Counsel and Secretary | ||||||